Author’s response to reviews

Title: Diabetes insipidus and panhypopituitarism as a first presentation of silent adenocarcinoma of lung: a case report and literature review

Authors:

Sirinart Sirinvaravong (sirinart.sir@mahidol.ac.th; sirinart.oh@gmail.com)

Peeradon Vibhatavata (p_wipatavut@hotmail.com)

Pawena Chunharojrith (paweharo@hotmail.com)

Pornsuk Cheunsuchon (pcheunsuchon@gmail.com)

Sutin Sriussadaporn (sutin.sri@mahidol.ac.th)

Version: 4 Date: 13 Oct 2019

Author’s response to reviews:

BMC Endocrine Disorders

13 October 2019

Dear the editor,

Reference number: BEND-D-19-00184

Thank you for your letter and comments concerning our manuscript entitled “Diabetes insipidus and panhypopituitarism as a first presentation of silent adenocarcinoma of lung: a case report and literature review: Reference number: BEND-D-19-00184”. We studied your comments carefully and made corrections in the manuscript which we hope to meet with your approval. We answered your comments in details in the following texts.

Replies to the editor comments

Editor Comments:
1. All sources of funding for the research reported should be declared in the "Funding" section. If no funding was obtained for your study we still require this section to be included with the statement “No funding was obtained for this study”. In the “Funding” section of your declarations, please clarify the role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Reply: We have added the statement “No funding was obtained for this study” into the manuscript (funding section, page 18, line 238)

2. Figure 5 is not cited in the body of the manuscript, please amend this.

Reply: We have cited figure 5 in the body of manuscript (case presentation section, page 10, line 129)

“A histopathological study revealed adenocarcinoma with the immunohistochemical staining positive for cytokeratin-7 and thyroid transcription factor-1 (TTF-1) but negative for cytokeratin-20, CDX-2 and GFAP (Figure 5).”

3. Please remove the CARE checklist and letter to the editor attachments, as they are no longer required at this stage.

Reply: CARE checklist and letter to the editor attachments have been removed.

4. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.

Reply: Clean version of the manuscript has been submitted. All track changes and highlights were removed. We also uploaded all figures as separate files.

5. In the Author’s contributions section, we defined Paweena Chunharojrith as PC1 and Pornsuk Cheunsuchon as “PC2” and added “PC2 provided pathological diagnosis” (page 18, line 241) and changed “PC” to “PC1” (page 18, line 240)

“SS1, PV, PC1 and SS2 diagnosed the patient, provided endocrine treatment, and acquired clinical data. PC2 provided pathological diagnosis.”
We really hope this modification meet with your approval.

Yours Sincerely,

Sirinart Sirinvaravong, MD

Division of Endocrinology and Metabolism, Department of Medicine
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Email: Sirinart.sir@mahidol.ac.th